Melphalan with or without siltuximab for multiple myeloma stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma and be scheduled for a stem cell transplant within 12 months of diagnosis.
- You must be at least 60 years old.
- You must have enough stem cells collected for the transplant.
- You must have good organ function, including heart, lung, and kidney tests within normal limits.
- You cannot have had prior treatment with drugs targeting IL-6 or its receptor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy drug combinations used before a stem cell transplant for multiple myeloma. The aim is to see if this new combination helps control the disease better before the transplant.
This trial tests whether the chemotherapy medicine treosulfan (Trecondi® Ideogen) works well and is safe for people with myeloma who are moving on to high-dose chemotherapy plus their own stem cell transplant. It may help strengthen the transplant “conditioning” treatment before the transplant.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.